TERBUNY, RUSSIA--(Marketwired - Jul 25, 2013) - Rafarma Pharmaceuticals, Inc. (
- The development of innovative Liposomal forms, anti-cancer and anti-tuberculosis drugs with certain targeted pharmacokinetic characteristics. The goal is to create parenteral medications based on non-dissolvable pharmaceutical substances using encapsulation and liposomes.
- The development of products with higher bioavailability (thereby increasing absorption rates) through modification of biopharmaceutical characteristics. The modifications are achieved by the creation of nano-crystals, which are formed through size reduction in the gas phase, as well as through synthetic crystallization.
These are only the first of several projects Rafarma is exploring in cooperation with Christian Albrecht University.
Rafarma CEO Dave Anderson stated, "This cooperative effort creates a synergy between a top-level research university and a state-of-the-art pharmaceutical production plant, which will open up many opportunities now and in the future for both Rafarma and Christian Albrecht University."
Newly-appointed board member and CAU faculty member, Dr. Hartwig Steckel [the Director of the Department of Pharmaceutics and Biopharmaceutics (Institute of Pharmacy) at Christian Albrecht University], commented, "This relationship is extremely exciting and I look forward to progressing rapidly with RAFARMA-CAU joint developments."
About Christian Albrecht University.
The University of Kiel, also known as Christian Albrecht University (CAU), was formally inaugurated in 1665. During its almost 350-year existence, the Christian-Albrechts-Universität in Kiel has given impetus and set new standards in many fields, including Pharmaceutical Technology. That much is clear from its roll-call of Nobel Prize winners. Some of the many recipients of this award to have taught at Kiel were Philipp Lenard (Physics 1905), Max Planck (Physics 1918) and Otto Diels (Chemistry 1950). Over the course of its history, the CAU has developed from a regional training academy to an internationally recognized university.
About Rafarma Pharmaceuticals, Inc.
Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.
For more information on Rafarma Pharmaceuticals, visit: http://RAFA.QualityStocks.net
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.
RELATED LINKS Website: www.Rafarma.com Facebook: www.facebook.com/Rafarmainfo Twitter: www.twitter.com/Rafarmainfo Videos: www.video.QualityStocks.net
Company Dave Anderson Rafarma Pharmaceuticals, Inc. 801.210.7135 Info@Rafarma.com
